Investigational A3 adenosine receptor targeting agents

Balázs Koscsó, Balázs Csóka, Pál Pacher, G. Haskó

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Introduction : Adenosine is an endogenous nucleoside that accumulates in the extracellular space in response to metabolic stress and cell damage. Extracellular adenosine is a signaling molecule that signals by activating four GPCRs: the A1, A2A, A2B and A3 receptors. Since the discovery of A3 adenosine receptors, accumulating evidence has identified these receptors as potential targets for therapeutic intervention. Areas covered : A3 adenosine receptors are expressed on the surface of most immune cell types, including neutrophils, macrophages, dendritic cells, lymphocytes and mast cells. A3 adenosine receptor activation on immune cells governs a broad array of immune cell functions, which include cytokine production, degranulation, chemotaxis, cytotoxicity, apoptosis and proliferation. In accordance with their multitudinous immunoregulatory actions, targeting A3 adenosine receptors has been shown to impact the course of a wide spectrum of immune-related diseases, such as asthma, rheumatoid arthritis, cancer, ischemia and inflammatory disorders. Expert opinion : Given the existence of both preclinical and early clinical data supporting the utility of A3 adenosine receptor ligands in treating immune-related diseases, further development of A3 adenosine receptor ligands is anticipated.

Original languageEnglish
Pages (from-to)757-768
Number of pages12
JournalExpert Opinion on Investigational Drugs
Volume20
Issue number6
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Adenosine A3 Receptors
Immune System Diseases
Adenosine
Ligands
Physiological Stress
Expert Testimony
Extracellular Space
Chemotaxis
Nucleosides
Mast Cells
Dendritic Cells
Rheumatoid Arthritis
Neutrophils
Ischemia
Asthma
Macrophages
Lymphocytes
Apoptosis
Cytokines

Keywords

  • A adenosine receptor
  • asthma
  • cancer
  • IB-MECA
  • rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Investigational A3 adenosine receptor targeting agents. / Koscsó, Balázs; Csóka, Balázs; Pacher, Pál; Haskó, G.

In: Expert Opinion on Investigational Drugs, Vol. 20, No. 6, 06.2011, p. 757-768.

Research output: Contribution to journalArticle

Koscsó, Balázs ; Csóka, Balázs ; Pacher, Pál ; Haskó, G. / Investigational A3 adenosine receptor targeting agents. In: Expert Opinion on Investigational Drugs. 2011 ; Vol. 20, No. 6. pp. 757-768.
@article{463ec9983ae1476ebe6b4afa8867d659,
title = "Investigational A3 adenosine receptor targeting agents",
abstract = "Introduction : Adenosine is an endogenous nucleoside that accumulates in the extracellular space in response to metabolic stress and cell damage. Extracellular adenosine is a signaling molecule that signals by activating four GPCRs: the A1, A2A, A2B and A3 receptors. Since the discovery of A3 adenosine receptors, accumulating evidence has identified these receptors as potential targets for therapeutic intervention. Areas covered : A3 adenosine receptors are expressed on the surface of most immune cell types, including neutrophils, macrophages, dendritic cells, lymphocytes and mast cells. A3 adenosine receptor activation on immune cells governs a broad array of immune cell functions, which include cytokine production, degranulation, chemotaxis, cytotoxicity, apoptosis and proliferation. In accordance with their multitudinous immunoregulatory actions, targeting A3 adenosine receptors has been shown to impact the course of a wide spectrum of immune-related diseases, such as asthma, rheumatoid arthritis, cancer, ischemia and inflammatory disorders. Expert opinion : Given the existence of both preclinical and early clinical data supporting the utility of A3 adenosine receptor ligands in treating immune-related diseases, further development of A3 adenosine receptor ligands is anticipated.",
keywords = "A adenosine receptor, asthma, cancer, IB-MECA, rheumatoid arthritis",
author = "Bal{\'a}zs Koscs{\'o} and Bal{\'a}zs Cs{\'o}ka and P{\'a}l Pacher and G. Hask{\'o}",
year = "2011",
month = "6",
doi = "10.1517/13543784.2011.573785",
language = "English",
volume = "20",
pages = "757--768",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "6",

}

TY - JOUR

T1 - Investigational A3 adenosine receptor targeting agents

AU - Koscsó, Balázs

AU - Csóka, Balázs

AU - Pacher, Pál

AU - Haskó, G.

PY - 2011/6

Y1 - 2011/6

N2 - Introduction : Adenosine is an endogenous nucleoside that accumulates in the extracellular space in response to metabolic stress and cell damage. Extracellular adenosine is a signaling molecule that signals by activating four GPCRs: the A1, A2A, A2B and A3 receptors. Since the discovery of A3 adenosine receptors, accumulating evidence has identified these receptors as potential targets for therapeutic intervention. Areas covered : A3 adenosine receptors are expressed on the surface of most immune cell types, including neutrophils, macrophages, dendritic cells, lymphocytes and mast cells. A3 adenosine receptor activation on immune cells governs a broad array of immune cell functions, which include cytokine production, degranulation, chemotaxis, cytotoxicity, apoptosis and proliferation. In accordance with their multitudinous immunoregulatory actions, targeting A3 adenosine receptors has been shown to impact the course of a wide spectrum of immune-related diseases, such as asthma, rheumatoid arthritis, cancer, ischemia and inflammatory disorders. Expert opinion : Given the existence of both preclinical and early clinical data supporting the utility of A3 adenosine receptor ligands in treating immune-related diseases, further development of A3 adenosine receptor ligands is anticipated.

AB - Introduction : Adenosine is an endogenous nucleoside that accumulates in the extracellular space in response to metabolic stress and cell damage. Extracellular adenosine is a signaling molecule that signals by activating four GPCRs: the A1, A2A, A2B and A3 receptors. Since the discovery of A3 adenosine receptors, accumulating evidence has identified these receptors as potential targets for therapeutic intervention. Areas covered : A3 adenosine receptors are expressed on the surface of most immune cell types, including neutrophils, macrophages, dendritic cells, lymphocytes and mast cells. A3 adenosine receptor activation on immune cells governs a broad array of immune cell functions, which include cytokine production, degranulation, chemotaxis, cytotoxicity, apoptosis and proliferation. In accordance with their multitudinous immunoregulatory actions, targeting A3 adenosine receptors has been shown to impact the course of a wide spectrum of immune-related diseases, such as asthma, rheumatoid arthritis, cancer, ischemia and inflammatory disorders. Expert opinion : Given the existence of both preclinical and early clinical data supporting the utility of A3 adenosine receptor ligands in treating immune-related diseases, further development of A3 adenosine receptor ligands is anticipated.

KW - A adenosine receptor

KW - asthma

KW - cancer

KW - IB-MECA

KW - rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=79955809218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955809218&partnerID=8YFLogxK

U2 - 10.1517/13543784.2011.573785

DO - 10.1517/13543784.2011.573785

M3 - Article

C2 - 21457061

AN - SCOPUS:79955809218

VL - 20

SP - 757

EP - 768

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 6

ER -